Maryam Asgari
Concepts (506)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 97 | 2024 | 762 | 22.510 |
Why?
| Carcinoma, Squamous Cell | 54 | 2024 | 584 | 14.320 |
Why?
| Carcinoma, Basal Cell | 22 | 2024 | 68 | 8.650 |
Why?
| Melanoma | 24 | 2023 | 631 | 4.720 |
Why?
| Keratosis, Actinic | 9 | 2024 | 11 | 4.100 |
Why?
| Dermatology | 12 | 2020 | 86 | 4.010 |
Why?
| Psoriasis | 8 | 2023 | 74 | 2.990 |
Why?
| Dermatologic Agents | 8 | 2019 | 57 | 2.830 |
Why?
| Genetic Loci | 6 | 2020 | 263 | 2.330 |
Why?
| Vitamin D | 10 | 2021 | 341 | 2.320 |
Why?
| Genetic Predisposition to Disease | 13 | 2022 | 2102 | 2.150 |
Why?
| Neoplasms, Multiple Primary | 4 | 2019 | 52 | 2.150 |
Why?
| California | 22 | 2018 | 363 | 2.120 |
Why?
| Dermatitis, Atopic | 6 | 2023 | 307 | 2.070 |
Why?
| Keratinocytes | 12 | 2020 | 216 | 2.030 |
Why?
| Risk Assessment | 20 | 2023 | 2975 | 1.880 |
Why?
| Mohs Surgery | 5 | 2021 | 25 | 1.700 |
Why?
| Transplant Recipients | 6 | 2021 | 140 | 1.650 |
Why?
| Incidence | 23 | 2024 | 2316 | 1.580 |
Why?
| Humans | 155 | 2024 | 114937 | 1.560 |
Why?
| Middle Aged | 68 | 2023 | 26806 | 1.550 |
Why?
| Aged | 62 | 2023 | 19122 | 1.550 |
Why?
| Risk Factors | 39 | 2024 | 8637 | 1.500 |
Why?
| Cohort Studies | 30 | 2023 | 4903 | 1.460 |
Why?
| Organ Transplantation | 7 | 2021 | 159 | 1.450 |
Why?
| Registries | 8 | 2018 | 1760 | 1.310 |
Why?
| Male | 88 | 2023 | 55663 | 1.310 |
Why?
| Fluorouracil | 5 | 2023 | 152 | 1.300 |
Why?
| Aged, 80 and over | 30 | 2020 | 6364 | 1.250 |
Why?
| Polymorphism, Single Nucleotide | 12 | 2024 | 1893 | 1.230 |
Why?
| Genome-Wide Association Study | 11 | 2024 | 1197 | 1.230 |
Why?
| Female | 86 | 2023 | 59581 | 1.200 |
Why?
| Biological Products | 3 | 2021 | 169 | 1.120 |
Why?
| Needs Assessment | 6 | 2018 | 315 | 1.110 |
Why?
| Immunosuppressive Agents | 6 | 2021 | 648 | 1.100 |
Why?
| Papillomaviridae | 4 | 2019 | 102 | 1.080 |
Why?
| Follow-Up Studies | 17 | 2020 | 4427 | 1.060 |
Why?
| Dietary Supplements | 5 | 2014 | 458 | 1.040 |
Why?
| Health Services Needs and Demand | 3 | 2012 | 244 | 1.030 |
Why?
| Adult | 49 | 2023 | 30608 | 0.990 |
Why?
| Skin Pigmentation | 3 | 2020 | 39 | 0.960 |
Why?
| Carcinoma, Merkel Cell | 5 | 2016 | 17 | 0.960 |
Why?
| Precision Medicine | 3 | 2022 | 339 | 0.950 |
Why?
| Retrospective Studies | 30 | 2023 | 12544 | 0.940 |
Why?
| Skin Diseases | 3 | 2023 | 122 | 0.930 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 299 | 0.900 |
Why?
| Delivery of Health Care | 4 | 2020 | 834 | 0.870 |
Why?
| Sex Factors | 6 | 2019 | 1721 | 0.860 |
Why?
| Sunlight | 4 | 2018 | 57 | 0.820 |
Why?
| Early Detection of Cancer | 3 | 2023 | 339 | 0.810 |
Why?
| Evidence-Based Medicine | 3 | 2019 | 675 | 0.770 |
Why?
| Carcinoma | 2 | 2020 | 199 | 0.760 |
Why?
| SEER Program | 3 | 2017 | 196 | 0.740 |
Why?
| Genetic Background | 1 | 2020 | 8 | 0.740 |
Why?
| Mendelian Randomization Analysis | 1 | 2021 | 43 | 0.740 |
Why?
| Hidradenitis Suppurativa | 1 | 2020 | 9 | 0.710 |
Why?
| Calcineurin Inhibitors | 1 | 2020 | 58 | 0.710 |
Why?
| Valproic Acid | 1 | 2020 | 43 | 0.700 |
Why?
| Antihypertensive Agents | 3 | 2018 | 429 | 0.680 |
Why?
| Point-of-Care Systems | 1 | 2021 | 139 | 0.680 |
Why?
| Drug Approval | 2 | 2019 | 78 | 0.670 |
Why?
| Orphan Drug Production | 1 | 2019 | 6 | 0.670 |
Why?
| Outpatient Clinics, Hospital | 1 | 2020 | 79 | 0.660 |
Why?
| Proportional Hazards Models | 9 | 2017 | 1080 | 0.660 |
Why?
| Women, Working | 1 | 2019 | 9 | 0.660 |
Why?
| HLA-DRB1 Chains | 1 | 2019 | 98 | 0.660 |
Why?
| Myotonic Dystrophy | 1 | 2019 | 5 | 0.650 |
Why?
| Databases, Factual | 8 | 2019 | 1125 | 0.650 |
Why?
| Salaries and Fringe Benefits | 1 | 2019 | 52 | 0.640 |
Why?
| Patient Care | 1 | 2019 | 103 | 0.640 |
Why?
| Epidemiologic Methods | 1 | 2019 | 72 | 0.640 |
Why?
| Managed Care Programs | 3 | 2017 | 133 | 0.640 |
Why?
| Young Adult | 19 | 2023 | 10478 | 0.630 |
Why?
| Physicians, Women | 1 | 2019 | 55 | 0.620 |
Why?
| Rare Diseases | 1 | 2019 | 89 | 0.620 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2020 | 198 | 0.620 |
Why?
| Electronic Health Records | 3 | 2021 | 802 | 0.620 |
Why?
| Photosensitizing Agents | 1 | 2018 | 26 | 0.620 |
Why?
| Models, Statistical | 2 | 2019 | 604 | 0.610 |
Why?
| Vitamin D Deficiency | 3 | 2021 | 158 | 0.610 |
Why?
| Genes, MHC Class II | 1 | 2018 | 70 | 0.610 |
Why?
| Aminoquinolines | 1 | 2017 | 20 | 0.600 |
Why?
| Vitamins | 5 | 2021 | 151 | 0.600 |
Why?
| Sex Distribution | 6 | 2017 | 336 | 0.600 |
Why?
| Lentigo | 1 | 2017 | 5 | 0.590 |
Why?
| Lithium | 1 | 2017 | 36 | 0.570 |
Why?
| DNA Virus Infections | 1 | 2017 | 3 | 0.570 |
Why?
| Haplotypes | 2 | 2018 | 453 | 0.570 |
Why?
| Mass Screening | 2 | 2023 | 1011 | 0.550 |
Why?
| Lymph Node Excision | 2 | 2015 | 142 | 0.550 |
Why?
| Opioid-Related Disorders | 2 | 2021 | 413 | 0.550 |
Why?
| Patient Satisfaction | 2 | 2011 | 583 | 0.550 |
Why?
| Epigenesis, Genetic | 1 | 2020 | 523 | 0.540 |
Why?
| Prognosis | 13 | 2018 | 3344 | 0.540 |
Why?
| Genomics | 2 | 2019 | 641 | 0.540 |
Why?
| Interferon Regulatory Factors | 1 | 2016 | 29 | 0.540 |
Why?
| Glucocorticoids | 1 | 2020 | 534 | 0.530 |
Why?
| HLA Antigens | 1 | 2017 | 224 | 0.510 |
Why?
| Bacterial Infections | 1 | 2017 | 219 | 0.510 |
Why?
| Research Design | 3 | 2019 | 932 | 0.510 |
Why?
| Quality Improvement | 3 | 2020 | 954 | 0.500 |
Why?
| Membrane Transport Proteins | 1 | 2016 | 138 | 0.500 |
Why?
| Community Health Services | 1 | 2017 | 212 | 0.500 |
Why?
| United States | 18 | 2023 | 12211 | 0.490 |
Why?
| Biomedical Research | 2 | 2019 | 585 | 0.490 |
Why?
| Antigens, Neoplasm | 1 | 2016 | 222 | 0.490 |
Why?
| Quality of Health Care | 1 | 2019 | 573 | 0.490 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 243 | 0.480 |
Why?
| Neoplasms, Unknown Primary | 1 | 2014 | 12 | 0.470 |
Why?
| Models, Biological | 2 | 2019 | 1630 | 0.470 |
Why?
| Neoplasms, Second Primary | 1 | 2015 | 94 | 0.460 |
Why?
| Sirolimus | 1 | 2015 | 181 | 0.460 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 666 | 0.460 |
Why?
| Analgesics, Opioid | 2 | 2021 | 773 | 0.450 |
Why?
| Adenocarcinoma, Papillary | 1 | 2013 | 9 | 0.450 |
Why?
| Herpes Zoster | 1 | 2018 | 333 | 0.450 |
Why?
| Odds Ratio | 7 | 2017 | 954 | 0.450 |
Why?
| Population Surveillance | 1 | 2016 | 392 | 0.450 |
Why?
| Confidence Intervals | 6 | 2017 | 309 | 0.440 |
Why?
| Kidney Transplantation | 1 | 2019 | 542 | 0.440 |
Why?
| Adolescent | 19 | 2023 | 17829 | 0.440 |
Why?
| Arthritis, Psoriatic | 1 | 2013 | 16 | 0.430 |
Why?
| Carcinoma, Large Cell | 1 | 2013 | 14 | 0.430 |
Why?
| Prevalence | 9 | 2024 | 2252 | 0.430 |
Why?
| Risk | 4 | 2019 | 815 | 0.420 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2013 | 64 | 0.420 |
Why?
| Mitochondria | 1 | 2018 | 751 | 0.420 |
Why?
| Logistic Models | 7 | 2018 | 1844 | 0.410 |
Why?
| Age Distribution | 4 | 2017 | 340 | 0.410 |
Why?
| Neuroectodermal Tumor, Melanotic | 1 | 2012 | 1 | 0.410 |
Why?
| Carotenoids | 1 | 2012 | 35 | 0.400 |
Why?
| Vitamin A | 1 | 2012 | 52 | 0.400 |
Why?
| Epidermis | 1 | 2012 | 149 | 0.390 |
Why?
| Hypertension | 3 | 2018 | 1059 | 0.390 |
Why?
| Skin Aging | 1 | 2011 | 19 | 0.390 |
Why?
| Lymph Nodes | 1 | 2014 | 425 | 0.390 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 863 | 0.390 |
Why?
| Surgery, Plastic | 1 | 2011 | 25 | 0.380 |
Why?
| Case-Control Studies | 7 | 2023 | 3008 | 0.380 |
Why?
| HIV Infections | 2 | 2017 | 2470 | 0.370 |
Why?
| Tea | 1 | 2011 | 10 | 0.370 |
Why?
| Skin | 5 | 2022 | 659 | 0.360 |
Why?
| Neoplasm Staging | 7 | 2023 | 1180 | 0.360 |
Why?
| Massachusetts | 3 | 2021 | 134 | 0.360 |
Why?
| Age Factors | 6 | 2018 | 2891 | 0.350 |
Why?
| Contraceptives, Oral | 1 | 2010 | 25 | 0.350 |
Why?
| United States Food and Drug Administration | 3 | 2019 | 172 | 0.330 |
Why?
| Global Health | 2 | 2024 | 288 | 0.310 |
Why?
| Patient Participation | 1 | 2011 | 360 | 0.310 |
Why?
| Sunbathing | 2 | 2018 | 13 | 0.300 |
Why?
| Disease Susceptibility | 2 | 2020 | 316 | 0.300 |
Why?
| Enhancer Elements, Genetic | 2 | 2020 | 152 | 0.290 |
Why?
| Genetic Association Studies | 2 | 2019 | 345 | 0.290 |
Why?
| Practice Patterns, Physicians' | 4 | 2017 | 1177 | 0.290 |
Why?
| Anticholesteremic Agents | 1 | 2009 | 128 | 0.290 |
Why?
| Head and Neck Neoplasms | 2 | 2014 | 436 | 0.290 |
Why?
| Comorbidity | 4 | 2018 | 1458 | 0.290 |
Why?
| Administration, Topical | 2 | 2017 | 139 | 0.290 |
Why?
| Education, Medical, Continuing | 3 | 2019 | 119 | 0.280 |
Why?
| Head Movements | 1 | 2007 | 18 | 0.280 |
Why?
| DNA, Viral | 2 | 2012 | 350 | 0.280 |
Why?
| Hemangiosarcoma | 1 | 2007 | 18 | 0.280 |
Why?
| Survival Rate | 5 | 2017 | 1644 | 0.270 |
Why?
| Reference Values | 3 | 2017 | 741 | 0.270 |
Why?
| Papillomavirus Infections | 4 | 2019 | 262 | 0.270 |
Why?
| Morbidity | 3 | 2016 | 277 | 0.270 |
Why?
| Prospective Studies | 8 | 2018 | 6218 | 0.270 |
Why?
| Polymorphism, Genetic | 3 | 2019 | 612 | 0.270 |
Why?
| Computational Biology | 2 | 2020 | 531 | 0.270 |
Why?
| Drug Costs | 2 | 2017 | 91 | 0.270 |
Why?
| Skin Diseases, Vesiculobullous | 1 | 2006 | 17 | 0.260 |
Why?
| Treatment Outcome | 9 | 2023 | 9105 | 0.260 |
Why?
| Delivery of Health Care, Integrated | 2 | 2022 | 229 | 0.260 |
Why?
| Neoplasm Invasiveness | 3 | 2017 | 445 | 0.260 |
Why?
| Calcifediol | 2 | 2018 | 29 | 0.260 |
Why?
| Antioxidants | 1 | 2009 | 530 | 0.260 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 372 | 0.250 |
Why?
| Surveys and Questionnaires | 8 | 2018 | 4635 | 0.240 |
Why?
| Nose | 1 | 2005 | 55 | 0.240 |
Why?
| Ultraviolet Rays | 4 | 2019 | 366 | 0.240 |
Why?
| CD4 Lymphocyte Count | 2 | 2017 | 257 | 0.240 |
Why?
| Infant, Premature, Diseases | 1 | 2006 | 89 | 0.240 |
Why?
| Photochemotherapy | 2 | 2021 | 29 | 0.230 |
Why?
| Fibrosarcoma | 1 | 2004 | 20 | 0.230 |
Why?
| Severity of Illness Index | 4 | 2023 | 2542 | 0.230 |
Why?
| Eosinophilia | 1 | 2006 | 186 | 0.230 |
Why?
| Surgical Flaps | 1 | 2005 | 121 | 0.220 |
Why?
| Child, Preschool | 7 | 2018 | 9086 | 0.220 |
Why?
| Molecular Sequence Annotation | 2 | 2020 | 81 | 0.220 |
Why?
| Patient Selection | 3 | 2013 | 642 | 0.220 |
Why?
| Feeding Behavior | 1 | 2009 | 572 | 0.220 |
Why?
| Disease Progression | 3 | 2020 | 2392 | 0.220 |
Why?
| Genotype | 3 | 2018 | 1775 | 0.220 |
Why?
| Insurance Claim Review | 2 | 2015 | 67 | 0.210 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 114 | 0.210 |
Why?
| Face | 2 | 2019 | 168 | 0.210 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2022 | 3 | 0.200 |
Why?
| Receptors, Calcitriol | 2 | 2012 | 53 | 0.200 |
Why?
| Quality of Life | 2 | 2017 | 2359 | 0.200 |
Why?
| Health Maintenance Organizations | 2 | 2014 | 93 | 0.200 |
Why?
| Eczema | 1 | 2023 | 82 | 0.200 |
Why?
| Ascorbic Acid | 1 | 2022 | 110 | 0.200 |
Why?
| Immunohistochemistry | 3 | 2019 | 1635 | 0.200 |
Why?
| Multifactorial Inheritance | 2 | 2019 | 125 | 0.200 |
Why?
| Neoplasms | 4 | 2021 | 2106 | 0.190 |
Why?
| Endorphins | 1 | 2021 | 7 | 0.190 |
Why?
| Rheumatic Diseases | 1 | 2022 | 49 | 0.190 |
Why?
| Blood Coagulation Disorders | 1 | 2004 | 192 | 0.190 |
Why?
| Immunocompromised Host | 3 | 2019 | 196 | 0.190 |
Why?
| Rituximab | 1 | 2022 | 151 | 0.190 |
Why?
| Forkhead Transcription Factors | 1 | 2022 | 171 | 0.190 |
Why?
| Biomarkers | 2 | 2017 | 3418 | 0.190 |
Why?
| Internet | 2 | 2017 | 599 | 0.190 |
Why?
| Electronics | 1 | 2021 | 66 | 0.190 |
Why?
| Child | 10 | 2018 | 18366 | 0.180 |
Why?
| Venous Thrombosis | 1 | 2022 | 142 | 0.180 |
Why?
| Wnt-5a Protein | 1 | 2020 | 18 | 0.180 |
Why?
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 21 | 0.180 |
Why?
| Causality | 1 | 2021 | 105 | 0.180 |
Why?
| Pulmonary Embolism | 1 | 2022 | 183 | 0.180 |
Why?
| Molecular Targeted Therapy | 2 | 2021 | 347 | 0.180 |
Why?
| Product Surveillance, Postmarketing | 1 | 2020 | 63 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1134 | 0.180 |
Why?
| Parents | 2 | 2018 | 1191 | 0.170 |
Why?
| Boston | 1 | 2020 | 75 | 0.170 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 1700 | 0.170 |
Why?
| Data Curation | 1 | 2019 | 11 | 0.170 |
Why?
| Xeroderma Pigmentosum | 1 | 2019 | 7 | 0.170 |
Why?
| Antirheumatic Agents | 1 | 2022 | 255 | 0.170 |
Why?
| Histocompatibility Testing | 1 | 2019 | 118 | 0.170 |
Why?
| Physicians, Primary Care | 2 | 2013 | 222 | 0.170 |
Why?
| Algorithms | 4 | 2016 | 1474 | 0.160 |
Why?
| Symbiosis | 1 | 2019 | 65 | 0.160 |
Why?
| Repressor Proteins | 1 | 2022 | 368 | 0.160 |
Why?
| Antibodies, Monoclonal | 2 | 2017 | 1270 | 0.160 |
Why?
| Torso | 1 | 2019 | 30 | 0.160 |
Why?
| Intention to Treat Analysis | 1 | 2018 | 68 | 0.160 |
Why?
| Quantitative Trait Loci | 1 | 2020 | 308 | 0.160 |
Why?
| Gene-Environment Interaction | 1 | 2020 | 184 | 0.160 |
Why?
| Administration, Cutaneous | 1 | 2018 | 117 | 0.160 |
Why?
| Predictive Value of Tests | 3 | 2013 | 1801 | 0.160 |
Why?
| Health Care Surveys | 2 | 2017 | 539 | 0.150 |
Why?
| Survival Analysis | 3 | 2016 | 1220 | 0.150 |
Why?
| Biopsy | 3 | 2013 | 1045 | 0.150 |
Why?
| Head | 1 | 2019 | 85 | 0.150 |
Why?
| Off-Label Use | 1 | 2018 | 51 | 0.150 |
Why?
| Extremities | 1 | 2019 | 113 | 0.150 |
Why?
| Longitudinal Studies | 2 | 2018 | 2382 | 0.150 |
Why?
| Policy | 1 | 2019 | 137 | 0.150 |
Why?
| Evidence-Based Practice | 1 | 2019 | 185 | 0.150 |
Why?
| Receptor, Melanocortin, Type 1 | 1 | 2017 | 8 | 0.150 |
Why?
| Documentation | 1 | 2019 | 169 | 0.150 |
Why?
| Vaccines | 1 | 2023 | 376 | 0.150 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 130 | 0.150 |
Why?
| Injections, Subcutaneous | 1 | 2018 | 134 | 0.150 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 817 | 0.150 |
Why?
| Immunotherapy | 1 | 2021 | 475 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2019 | 152 | 0.140 |
Why?
| Random Allocation | 1 | 2018 | 335 | 0.140 |
Why?
| Family | 2 | 2011 | 590 | 0.140 |
Why?
| Disease-Free Survival | 2 | 2016 | 623 | 0.140 |
Why?
| Ultraviolet Therapy | 1 | 2017 | 16 | 0.140 |
Why?
| Merkel cell polyomavirus | 1 | 2016 | 3 | 0.140 |
Why?
| Cryosurgery | 2 | 2021 | 52 | 0.140 |
Why?
| Neoplasms, Radiation-Induced | 1 | 2017 | 66 | 0.140 |
Why?
| Drug Utilization | 1 | 2017 | 167 | 0.140 |
Why?
| Tumor Virus Infections | 1 | 2016 | 43 | 0.140 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2016 | 23 | 0.140 |
Why?
| Genotyping Techniques | 1 | 2016 | 69 | 0.130 |
Why?
| Paraneoplastic Syndromes | 1 | 2016 | 12 | 0.130 |
Why?
| Drug Prescriptions | 1 | 2018 | 239 | 0.130 |
Why?
| Immunity | 1 | 2017 | 121 | 0.130 |
Why?
| Sunburn | 2 | 2018 | 25 | 0.130 |
Why?
| International Classification of Diseases | 2 | 2015 | 117 | 0.130 |
Why?
| Genetic Variation | 1 | 2021 | 876 | 0.130 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2023 | 1183 | 0.130 |
Why?
| Intention | 1 | 2017 | 143 | 0.130 |
Why?
| Spondylarthritis | 1 | 2016 | 36 | 0.130 |
Why?
| Aspergillus | 1 | 2015 | 16 | 0.130 |
Why?
| Spondylitis, Ankylosing | 1 | 2016 | 43 | 0.130 |
Why?
| Practice Guidelines as Topic | 2 | 2021 | 1400 | 0.130 |
Why?
| Viral Load | 1 | 2017 | 405 | 0.130 |
Why?
| Gene Frequency | 1 | 2017 | 481 | 0.130 |
Why?
| Body Mass Index | 2 | 2021 | 1961 | 0.130 |
Why?
| Aspergillosis | 1 | 2015 | 23 | 0.130 |
Why?
| Pharmaceutical Services | 1 | 2016 | 79 | 0.130 |
Why?
| Linear Models | 1 | 2018 | 770 | 0.130 |
Why?
| Voriconazole | 1 | 2015 | 24 | 0.130 |
Why?
| Cause of Death | 1 | 2017 | 363 | 0.120 |
Why?
| Transcriptome | 1 | 2020 | 728 | 0.120 |
Why?
| Surgeons | 1 | 2019 | 237 | 0.120 |
Why?
| Referral and Consultation | 1 | 2020 | 634 | 0.120 |
Why?
| Patient Education as Topic | 1 | 2020 | 678 | 0.120 |
Why?
| Cluster Analysis | 1 | 2016 | 460 | 0.120 |
Why?
| Fetal Blood | 1 | 2017 | 270 | 0.120 |
Why?
| Sex Characteristics | 1 | 2019 | 635 | 0.120 |
Why?
| Motivation | 1 | 2019 | 495 | 0.120 |
Why?
| Stevens-Johnson Syndrome | 1 | 2015 | 34 | 0.120 |
Why?
| Health Personnel | 2 | 2017 | 574 | 0.120 |
Why?
| Sebaceous Glands | 1 | 2014 | 4 | 0.120 |
Why?
| Kava | 1 | 2014 | 2 | 0.120 |
Why?
| Transcription, Genetic | 1 | 2020 | 1317 | 0.120 |
Why?
| Multivariate Analysis | 3 | 2016 | 1440 | 0.120 |
Why?
| Drug Eruptions | 1 | 2014 | 26 | 0.120 |
Why?
| Plant Preparations | 1 | 2014 | 23 | 0.120 |
Why?
| Infant | 4 | 2014 | 7937 | 0.120 |
Why?
| Stomach Neoplasms | 1 | 2015 | 65 | 0.120 |
Why?
| Animals | 7 | 2021 | 31839 | 0.120 |
Why?
| Phytotherapy | 1 | 2014 | 66 | 0.120 |
Why?
| Infant, Newborn | 3 | 2014 | 5035 | 0.110 |
Why?
| Gastrectomy | 1 | 2015 | 82 | 0.110 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 692 | 0.110 |
Why?
| Exanthema | 1 | 2014 | 76 | 0.110 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2014 | 100 | 0.110 |
Why?
| Signal Transduction | 2 | 2019 | 4525 | 0.110 |
Why?
| Mutation | 3 | 2019 | 3354 | 0.110 |
Why?
| Biomarkers, Tumor | 1 | 2019 | 1054 | 0.110 |
Why?
| Clinical Coding | 1 | 2013 | 19 | 0.110 |
Why?
| Lung Transplantation | 1 | 2015 | 246 | 0.110 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1148 | 0.110 |
Why?
| Systematized Nomenclature of Medicine | 1 | 2013 | 12 | 0.110 |
Why?
| Arthritis, Juvenile | 1 | 2013 | 42 | 0.110 |
Why?
| Lip Neoplasms | 1 | 2012 | 1 | 0.110 |
Why?
| Mortality | 1 | 2015 | 288 | 0.110 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2012 | 447 | 0.100 |
Why?
| Sunscreening Agents | 1 | 2012 | 17 | 0.100 |
Why?
| Hydrochlorothiazide | 1 | 2012 | 8 | 0.100 |
Why?
| Nifedipine | 1 | 2012 | 29 | 0.100 |
Why?
| Genetic Testing | 2 | 2019 | 379 | 0.100 |
Why?
| Calcium, Dietary | 1 | 2012 | 55 | 0.100 |
Why?
| Methotrexate | 1 | 2013 | 228 | 0.100 |
Why?
| Health Services Accessibility | 1 | 2018 | 765 | 0.100 |
Why?
| Professional Competence | 1 | 2012 | 84 | 0.100 |
Why?
| Graft Rejection | 1 | 2015 | 516 | 0.100 |
Why?
| Computer-Assisted Instruction | 1 | 2012 | 64 | 0.100 |
Why?
| Fees and Charges | 1 | 2011 | 9 | 0.100 |
Why?
| Private Practice | 1 | 2011 | 20 | 0.100 |
Why?
| Diagnosis, Differential | 3 | 2007 | 1355 | 0.100 |
Why?
| Marital Status | 1 | 2011 | 41 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2023 | 1870 | 0.100 |
Why?
| Electrosurgery | 1 | 2012 | 43 | 0.100 |
Why?
| Nutrition Surveys | 1 | 2012 | 224 | 0.100 |
Why?
| Hedgehog Proteins | 1 | 2012 | 173 | 0.100 |
Why?
| Homeodomain Proteins | 1 | 2015 | 464 | 0.090 |
Why?
| Food | 1 | 2012 | 160 | 0.090 |
Why?
| Postoperative Hemorrhage | 1 | 2011 | 75 | 0.090 |
Why?
| Curriculum | 1 | 2017 | 845 | 0.090 |
Why?
| Physicians | 1 | 2019 | 772 | 0.090 |
Why?
| Basal Cell Nevus Syndrome | 1 | 2010 | 5 | 0.090 |
Why?
| Immune Tolerance | 1 | 2012 | 328 | 0.090 |
Why?
| Program Development | 1 | 2012 | 345 | 0.090 |
Why?
| Aspirin | 1 | 2013 | 324 | 0.090 |
Why?
| DNA Damage | 1 | 2012 | 357 | 0.090 |
Why?
| Faculty, Medical | 1 | 2012 | 232 | 0.090 |
Why?
| Neoplasms, Basal Cell | 1 | 2009 | 3 | 0.090 |
Why?
| Family Relations | 1 | 2010 | 85 | 0.090 |
Why?
| Cross-Sectional Studies | 2 | 2018 | 4407 | 0.090 |
Why?
| Education, Medical | 1 | 2012 | 222 | 0.080 |
Why?
| Life Style | 1 | 2012 | 430 | 0.080 |
Why?
| Behavior Therapy | 1 | 2011 | 226 | 0.080 |
Why?
| Genetic Counseling | 1 | 2009 | 65 | 0.080 |
Why?
| Lung Neoplasms | 1 | 2022 | 2223 | 0.080 |
Why?
| Phylogeny | 2 | 2015 | 795 | 0.080 |
Why?
| Eggs | 1 | 2009 | 30 | 0.080 |
Why?
| Fishes | 1 | 2009 | 81 | 0.080 |
Why?
| Energy Metabolism | 1 | 2013 | 724 | 0.080 |
Why?
| Northwestern United States | 1 | 2008 | 53 | 0.080 |
Why?
| Adenocarcinoma | 1 | 2015 | 801 | 0.080 |
Why?
| Time Factors | 3 | 2017 | 6125 | 0.080 |
Why?
| Milk | 1 | 2009 | 124 | 0.080 |
Why?
| Pemphigus | 1 | 2007 | 8 | 0.080 |
Why?
| Health Behavior | 2 | 2017 | 704 | 0.070 |
Why?
| Prostatic Neoplasms | 1 | 2015 | 925 | 0.070 |
Why?
| Cervix Uteri | 1 | 2007 | 45 | 0.070 |
Why?
| Postoperative Complications | 2 | 2015 | 2133 | 0.070 |
Why?
| Arthritis, Rheumatoid | 1 | 2015 | 1002 | 0.070 |
Why?
| Risk Reduction Behavior | 1 | 2009 | 200 | 0.070 |
Why?
| Head-Down Tilt | 1 | 2007 | 5 | 0.070 |
Why?
| Torsion Abnormality | 1 | 2007 | 17 | 0.070 |
Why?
| Psychological Theory | 1 | 2007 | 94 | 0.070 |
Why?
| Clinical Competence | 1 | 2013 | 901 | 0.070 |
Why?
| Disclosure | 1 | 2007 | 101 | 0.070 |
Why?
| Sweat Gland Diseases | 1 | 2006 | 1 | 0.070 |
Why?
| Eccrine Glands | 1 | 2006 | 2 | 0.070 |
Why?
| Eosinophil-Derived Neurotoxin | 1 | 2006 | 3 | 0.070 |
Why?
| Mupirocin | 1 | 2006 | 7 | 0.070 |
Why?
| Hamartoma | 1 | 2006 | 21 | 0.070 |
Why?
| Eosinophil Major Basic Protein | 1 | 2006 | 6 | 0.070 |
Why?
| Arteriovenous Malformations | 1 | 2006 | 24 | 0.070 |
Why?
| Environmental Exposure | 1 | 2009 | 377 | 0.070 |
Why?
| Bandages | 1 | 2006 | 31 | 0.060 |
Why?
| Primary Health Care | 2 | 2017 | 1515 | 0.060 |
Why?
| Anti-Bacterial Agents | 2 | 2023 | 1477 | 0.060 |
Why?
| Acetaminophen | 1 | 2008 | 238 | 0.060 |
Why?
| Sodium Chloride | 1 | 2006 | 136 | 0.060 |
Why?
| Communication | 1 | 2010 | 749 | 0.060 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 58 | 0.060 |
Why?
| Vaccination | 2 | 2023 | 1205 | 0.060 |
Why?
| Necrosis | 1 | 2005 | 210 | 0.060 |
Why?
| Patient-Centered Care | 1 | 2009 | 473 | 0.060 |
Why?
| Societies, Medical | 2 | 2018 | 677 | 0.060 |
Why?
| Cyclooxygenase 2 | 1 | 2004 | 164 | 0.060 |
Why?
| Isoenzymes | 1 | 2004 | 285 | 0.060 |
Why?
| Skin Transplantation | 1 | 2004 | 57 | 0.060 |
Why?
| New York | 1 | 2023 | 106 | 0.050 |
Why?
| Public Health | 1 | 2007 | 434 | 0.050 |
Why?
| Socioeconomic Factors | 2 | 2021 | 1081 | 0.050 |
Why?
| Mucous Membrane | 1 | 2023 | 108 | 0.050 |
Why?
| Hand | 1 | 2004 | 134 | 0.050 |
Why?
| Infant, Premature | 1 | 2006 | 478 | 0.050 |
Why?
| Diclofenac | 1 | 2021 | 14 | 0.050 |
Why?
| Hospitalization | 2 | 2023 | 1754 | 0.050 |
Why?
| Delphi Technique | 1 | 2021 | 162 | 0.050 |
Why?
| Combined Modality Therapy | 1 | 2023 | 1126 | 0.040 |
Why?
| Adrenal Cortex Hormones | 1 | 2004 | 499 | 0.040 |
Why?
| B7-H1 Antigen | 1 | 2022 | 142 | 0.040 |
Why?
| Ligands | 1 | 2022 | 565 | 0.040 |
Why?
| Ipilimumab | 1 | 2019 | 29 | 0.040 |
Why?
| Oncogenes | 1 | 2019 | 108 | 0.040 |
Why?
| Membrane Proteins | 1 | 2004 | 1022 | 0.040 |
Why?
| Carcinogenesis | 1 | 2019 | 180 | 0.040 |
Why?
| Keratoacanthoma | 1 | 2017 | 2 | 0.040 |
Why?
| Photosensitivity Disorders | 1 | 2017 | 7 | 0.040 |
Why?
| Capecitabine | 1 | 2017 | 45 | 0.040 |
Why?
| PUVA Therapy | 1 | 1997 | 5 | 0.040 |
Why?
| Retinoids | 1 | 2017 | 31 | 0.040 |
Why?
| Risk Adjustment | 1 | 2018 | 75 | 0.040 |
Why?
| Reimbursement Mechanisms | 1 | 2018 | 77 | 0.040 |
Why?
| Vitamin B Complex | 1 | 2017 | 38 | 0.040 |
Why?
| Databases, Genetic | 1 | 2018 | 206 | 0.040 |
Why?
| Observational Studies as Topic | 1 | 2018 | 90 | 0.040 |
Why?
| Niacinamide | 1 | 2017 | 64 | 0.040 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2017 | 82 | 0.040 |
Why?
| Primary Prevention | 1 | 2018 | 171 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 2017 | 182 | 0.040 |
Why?
| Pregnancy Trimester, Second | 1 | 2017 | 66 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2001 | 934 | 0.030 |
Why?
| Rheumatologists | 1 | 2016 | 12 | 0.030 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 312 | 0.030 |
Why?
| Pregnancy Trimester, First | 1 | 2017 | 126 | 0.030 |
Why?
| Computers | 1 | 2016 | 60 | 0.030 |
Why?
| Drugs, Generic | 1 | 2016 | 18 | 0.030 |
Why?
| RNA, Viral | 1 | 2019 | 566 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 183 | 0.030 |
Why?
| Sampling Studies | 1 | 2016 | 93 | 0.030 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1361 | 0.030 |
Why?
| Medical Records Systems, Computerized | 1 | 2016 | 90 | 0.030 |
Why?
| Mice | 3 | 2021 | 14936 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 316 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 530 | 0.030 |
Why?
| Research | 1 | 2018 | 395 | 0.030 |
Why?
| Pandemics | 1 | 2023 | 1325 | 0.030 |
Why?
| Pharmacoepidemiology | 1 | 2015 | 20 | 0.030 |
Why?
| Health Expenditures | 1 | 2016 | 171 | 0.030 |
Why?
| Gene Expression | 1 | 2020 | 1422 | 0.030 |
Why?
| Disease Management | 1 | 2018 | 563 | 0.030 |
Why?
| Erythema | 1 | 2014 | 25 | 0.030 |
Why?
| Antifungal Agents | 1 | 2015 | 129 | 0.030 |
Why?
| Papillomavirus Vaccines | 1 | 2017 | 223 | 0.030 |
Why?
| Prenatal Care | 1 | 2017 | 255 | 0.030 |
Why?
| Germ-Line Mutation | 1 | 2015 | 131 | 0.030 |
Why?
| Phototherapy | 1 | 2013 | 24 | 0.030 |
Why?
| Infliximab | 1 | 2013 | 94 | 0.030 |
Why?
| Graft Survival | 1 | 2015 | 452 | 0.030 |
Why?
| Computer User Training | 1 | 2012 | 6 | 0.030 |
Why?
| Medicaid | 1 | 2016 | 407 | 0.030 |
Why?
| Feasibility Studies | 1 | 2015 | 737 | 0.030 |
Why?
| Codon | 1 | 2012 | 86 | 0.020 |
Why?
| Washington | 1 | 2012 | 133 | 0.020 |
Why?
| Ibuprofen | 1 | 2012 | 74 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2018 | 2770 | 0.020 |
Why?
| Medicare | 1 | 2016 | 666 | 0.020 |
Why?
| Postmenopause | 1 | 2013 | 303 | 0.020 |
Why?
| Regression Analysis | 1 | 2012 | 947 | 0.020 |
Why?
| Coccidioidomycosis | 1 | 1970 | 7 | 0.020 |
Why?
| Histoplasmosis | 1 | 1970 | 16 | 0.020 |
Why?
| Early Diagnosis | 1 | 2011 | 217 | 0.020 |
Why?
| Lipids | 1 | 2013 | 582 | 0.020 |
Why?
| Michigan | 1 | 2009 | 96 | 0.020 |
Why?
| Skin Tests | 1 | 1970 | 122 | 0.020 |
Why?
| Family Characteristics | 1 | 2010 | 152 | 0.020 |
Why?
| Health Surveys | 1 | 1970 | 443 | 0.020 |
Why?
| Papanicolaou Test | 1 | 2007 | 39 | 0.020 |
Why?
| Vaginal Smears | 1 | 2007 | 50 | 0.020 |
Why?
| Blood Pressure | 1 | 2013 | 1537 | 0.020 |
Why?
| Psychology | 1 | 2007 | 81 | 0.020 |
Why?
| Precancerous Conditions | 1 | 2007 | 158 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2011 | 1215 | 0.020 |
Why?
| Pregnancy | 1 | 2017 | 5527 | 0.020 |
Why?
| Colorectal Neoplasms | 1 | 2012 | 621 | 0.020 |
Why?
| Blood Glucose | 1 | 2013 | 1821 | 0.010 |
Why?
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 1997 | 995 | 0.010 |
Why?
| Histoplasmin | 1 | 1970 | 1 | 0.010 |
Why?
| Mass Chest X-Ray | 1 | 1970 | 4 | 0.010 |
Why?
| Coccidioides | 1 | 1970 | 4 | 0.010 |
Why?
| Histoplasma | 1 | 1970 | 14 | 0.010 |
Why?
| Iran | 1 | 1970 | 35 | 0.010 |
Why?
| Blood Cell Count | 1 | 1970 | 52 | 0.010 |
Why?
| Occupations | 1 | 1970 | 36 | 0.010 |
Why?
| Tuberculin Test | 1 | 1970 | 32 | 0.010 |
Why?
| Climate | 1 | 1970 | 85 | 0.010 |
Why?
| Antigens | 1 | 1970 | 318 | 0.000 |
Why?
| Sputum | 1 | 1970 | 285 | 0.000 |
Why?
| Soil Microbiology | 1 | 1970 | 177 | 0.000 |
Why?
| Rural Population | 1 | 1970 | 447 | 0.000 |
Why?
|
|
Asgari's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|